Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Long-Term Investments (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Long-Term Investments for 11 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 92.02% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 92.02% year-over-year, with the annual reading at $5.2 million for FY2025, 92.02% down from the prior year.
  • Long-Term Investments hit $5.2 million in Q4 2025 for Voyager Therapeutics, down from $20.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $65.7 million in Q4 2024 to a low of $1.0 million in Q1 2024.
  • Historically, Long-Term Investments has averaged $11.2 million across 5 years, with a median of $1.8 million in 2021.
  • Biggest YoY gain for Long-Term Investments was 5810.3% in 2025; the steepest drop was 92.02% in 2025.
  • Year by year, Long-Term Investments stood at $1.8 million in 2021, then fell by 14.84% to $1.5 million in 2022, then increased by 5.15% to $1.6 million in 2023, then surged by 4024.54% to $65.7 million in 2024, then plummeted by 92.02% to $5.2 million in 2025.
  • Business Quant data shows Long-Term Investments for VYGR at $5.2 million in Q4 2025, $20.1 million in Q3 2025, and $46.4 million in Q2 2025.